Insider Trading: Sardar Biglari Obtained 271 Shares of Biglari Holdings Inc. (BH); 4 Bullish Analysts Covering Regenxbio Inc. (RGNX)

January 13, 2018 - By Shannon Black

Among 4 analysts covering Regenxbio (NASDAQ:RGNX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Regenxbio has $33 highest and $29 lowest target. $31’s average target is 1.81% above currents $30.45 stock price. Regenxbio had 4 analyst reports since October 12, 2015 according to SRatingsIntel. The stock of Regenxbio Inc. (NASDAQ:RGNX) earned “Buy” rating by Bank of America on Monday, October 12. The stock of Regenxbio Inc. (NASDAQ:RGNX) has “Buy” rating given on Tuesday, October 20 by Chardan Capital Markets. The firm has “Overweight” rating by Morgan Stanley given on Tuesday, October 13. The stock of Regenxbio Inc. (NASDAQ:RGNX) has “Overweight” rating given on Monday, October 12 by Piper Jaffray. See Regenxbio Inc. (NASDAQ:RGNX) latest ratings:

Insider transaction totalling about $113,729 US Dollars was revealed online in a public report submitted to the SEC on 12/01/2018. According to which, Sardar Biglari, the director of Biglari Holdings Inc also an insider of the corporation had purchased a total of 271 shares [Bold1 ] – ( at $419.7 a share ). Sardar is trying to silently increase his company’s share, same as he did in the last 30 days. He bought another 26,053 shares worth $10.70 million USD. Due to the size of the purchase there is little chance that it will remain disregarded. Sardar Biglari today holds 1.09 million shares or 52.54% of Biglari Holdings Inc’s market cap.

The stock increased 1.84% or $0.55 during the last trading session, reaching $30.45. About 642,017 shares traded or 70.71% up from the average. Regenxbio Inc. (NASDAQ:RGNX) has risen 51.43% since January 13, 2017 and is uptrending. It has outperformed by 34.73% the S&P500.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. The company has market cap of $948.37 million. The Company’s gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. It currently has negative earnings. The companyÂ’s lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration.

Since December 11, 2017, it had 4 insider purchases, and 0 sales for $7.75 million activity. BIGLARI – SARDAR bought $2.33M worth of Biglari Holdings Inc. (NYSE:BH) on Thursday, December 14.

Investors sentiment increased to 1.31 in Q3 2017. Its up 0.19, from 1.12 in 2017Q2. It improved, as 7 investors sold Biglari Holdings Inc. shares while 29 reduced holdings. 14 funds opened positions while 33 raised stakes. 1.81 million shares or 1.03% less from 1.83 million shares in 2017Q2 were reported. 2,794 were reported by First Advisors Lp. Malaga Cove Cap Ltd Liability holds 100 shares. River Road Asset Management Limited Co has invested 0.42% in Biglari Holdings Inc. (NYSE:BH). Janney Montgomery Scott Ltd Limited Liability Company invested in 6,064 shares. Gamco Investors Et Al reported 73,077 shares stake. Moreover, Wells Fargo & Co Mn has 0% invested in Biglari Holdings Inc. (NYSE:BH). Jacobs Levy Equity Mngmt Inc accumulated 2,121 shares. National Bank & Trust Of Montreal Can reported 0% in Biglari Holdings Inc. (NYSE:BH). M&R Mngmt Incorporated owns 5 shares for 0% of their portfolio. Steinberg Glob Asset Management has invested 0.06% in Biglari Holdings Inc. (NYSE:BH). Citigroup Inc reported 0% of its portfolio in Biglari Holdings Inc. (NYSE:BH). The Wisconsin-based Mason Street Advsr Lc has invested 0% in Biglari Holdings Inc. (NYSE:BH). American Int Group Incorporated accumulated 804 shares. 350 were accumulated by First Manhattan. Biglari reported 1.05 million shares.

The stock decreased 0.33% or $1.41 during the last trading session, reaching $424.04. About 4,545 shares traded. Biglari Holdings Inc. (NYSE:BH) has risen 5.31% since January 13, 2017 and is uptrending. It has underperformed by 11.39% the S&P500.

Biglari Holdings Inc., through its subsidiaries, operates and franchises restaurants in the United States. The company has market cap of $876.75 million. The firm owns, operates, and franchises restaurants under restaurant concepts, including Steak n Shake, an American brand serving premium burgers and milk shakes; and Western, which offers signature steak dishes and other American menu items, as well operates other concepts, such as Great American Steak & Buffet and Wood Grill Buffet consisting of hot and cold food buffet style dining. It has a 10.09 P/E ratio. As of December 31, 2016, it operated 417 Steak n Shake company-operated restaurants and 173 franchised units; and 3 Western company-operated restaurants and 64 franchised units.